NEW YORK, August 4, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), WellPoint Inc. (NYSE: WLP), Edwards Lifesciences Corp. (NYSE: EW), Humana Inc. (NYSE: HUM) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5412-100free.
--
Regeneron Pharmaceuticals Inc. Research Reports
On July 30, 2014, Regeneron Pharmaceuticals Inc. (Regeneron) and Sanofi jointly announced that both the Companies are planning to use a U.S. Food and Drug Administration (FDA) rare pediatric disease priority review voucher in connection with the Biologics License Application (BLA) submission for alirocumab. Regeneron informed that this priority review voucher allows the holder to designate a BLA for priority review, which provides for an expedited 6-month review from the filing date instead of the standard 10-month review. The Company's indirect, wholly-owned subsidiary Regeneron Ireland purchased this voucher from BioMarin GALNS Ltd., a direct, wholly-owned subsidiary of BioMarin Pharmaceutical, Inc., which had received it through the FDA's Rare Pediatric Disease Priority Review Voucher Program. Both Sanofi and Regeneron will share the purchase price of $67.5 million equally. The full research reports on Regeneron are available to download free of charge at:
http://www.analystsreview.com/Aug-04-2014/REGN/report.pdf
--
WellPoint Inc. Research Reports
On July 30, 2014, WellPoint Inc. (WellPoint) reported Q2 2014 results with total operating revenue of $18.2 billion, up 4.2% YoY, reflecting increase in premium to cover overall cost trends and new fees associated with Health Care Reform, as well as higher enrollment in the Medicaid, Individual and Commercial self-funded businesses, partially offset by decline in revenues due to the State of New York contract conversion to a self-funded arrangement, as previously disclosed, and a decline in Small Group and Medicare enrollment. The Company's Q2 2014 net income came in at $731.1 million or $2.56 per diluted share, compared to net income of $800.1 million or $2.64 per diluted share in Q2 2013. The Company's H1 2014 total operating revenues improved 2.7% YoY to $35.9 billion. H1 2014 net income stood at $1.4 billion or $4.95 per diluted share, compared to net income of $1.7 billion or $5.53 in H1 2013. The full research reports on WellPoint are available to download free of charge at:
http://www.analystsreview.com/Aug-04-2014/WLP/report.pdf
--
Edwards Lifesciences Corp. Research Reports
On July 29, 2014, Edwards Lifesciences Corp. (Edwards) released its Q2 2014 and H1 2014 financial results with intellectual property litigation income of $747.4 million. The Company reported Q2 2014 net sales of $575.1 million, up 11.2% YoY. According to analysts estimate compiled by Thomson Reuters I/B/E/S, the Company was expected to post Q2 2014 EPS of $0.77 on sales of $544.6 million. Q2 2014 net income came in at $547.0 million or $5.09 per diluted share, compared to net profit of $93.3 million or $0.81 per diluted share in Q2 2013. The Company's H1 2014 net sales improved 8.2% YoY to $1.1 billion. The Company's H1 2014 net income stood at $607.3 million or $5.63 per diluted share, compared to net income of $237.2 million or $2.05 per diluted share in H1 2013. The full research reports on Edwards are available to download free of charge at:
http://www.analystsreview.com/Aug-04-2014/EW/report.pdf
--
Humana Inc. Research Reports
On July 30, 2014, Humana Inc. (Humana) posted Q2 2014 results with total revenues of $12.2 billion, up 18.4% YoY, surpassing Zacks consensus revenue estimate of $11.9 billion. During the quarter, the Company's premiums and services revenue improved 18.6% YoY to $12.1 billion driven by higher medical membership in the Retail segment and higher group Medicare Advantage membership in the Employer Group segment. The Company's Q2 2014 net income came in at $344 million or $2.19 per diluted share, compared to net income of $420 million or $2.63 per diluted share in Q2 2013. The Company's H1 2014 total revenues improved 15.0% YoY to $23.9 billion. H1 2014 net income was $712 million or $4.54 per diluted share, compared to net income of $893 million or $5.58 per diluted share in H1 2013. For full-year 2014, the Company expects EPS in the range of $7.25 - $7.75. The full research reports on Humana are available to download free of charge at:
http://www.analystsreview.com/Aug-04-2014/HUM/report.pdf
--
Celgene Corporation Research Reports
On July 24, 2014, Celgene Corporation (Celgene) released its Q2 2014 and H1 2014 earnings. The Company reported Q2 2014 total revenues of $1.9 billion, up 17.1% YoY. Q2 2014 net income came in at $597.8 million or $0.72 per diluted share, compared to net income of $478.1 million or $0.56 per diluted share in Q2 2013. The Company's H1 2014 total revenue improved 17.6% YoY to $3.6 billion. H1 2014 net income came in at $877.5 million or $1.05 per diluted share, compared to net income of $863.0 million or $1.00 per diluted share in H1 2013. For full-year 2014, Celgene expects total revenue of c. $7.6 billion and diluted EPS in the range of $2.46 - $2.55. The full research reports on Celgene are available to download free of charge at:
http://www.analystsreview.com/Aug-04-2014/CELG/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
